These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 15464660)
1. Hepatitis C and steatosis. Dev A; Patel K; McHutchison JG Clin Liver Dis; 2004 Nov; 8(4):881-92, ix. PubMed ID: 15464660 [TBL] [Abstract][Full Text] [Related]
2. Steatosis and chronic hepatitis C virus infection: mechanisms and significance. Patel K; Zekry A; McHutchison JG Clin Liver Dis; 2005 Aug; 9(3):399-410, vi. PubMed ID: 16023973 [TBL] [Abstract][Full Text] [Related]
3. Influence of metabolic syndrome, viral genotype and antiviral therapy on superimposed fatty liver disease in chronic hepatitis C. Liu CJ; Jeng YM; Chen PJ; Lai MY; Yang HC; Huang WL; Kao JH; Chen DS Antivir Ther; 2005; 10(3):405-15. PubMed ID: 15918331 [TBL] [Abstract][Full Text] [Related]
4. Hepatic steatosis and hepatitis C: Still unhappy bedfellows? Hwang SJ; Lee SD J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():96-101. PubMed ID: 21199519 [TBL] [Abstract][Full Text] [Related]
5. Steatosis, insulin resistance and fibrosis progression in chronic hepatitis C. Castera L Minerva Gastroenterol Dietol; 2006 Jun; 52(2):125-34. PubMed ID: 16557184 [TBL] [Abstract][Full Text] [Related]
6. Hepatitis C and steatosis: a reappraisal. Lonardo A; Loria P; Adinolfi LE; Carulli N; Ruggiero G J Viral Hepat; 2006 Feb; 13(2):73-80. PubMed ID: 16436124 [TBL] [Abstract][Full Text] [Related]
7. Steatosis and insulin resistance in response to treatment of chronic hepatitis C. Negro F J Viral Hepat; 2012 Jan; 19 Suppl 1():42-7. PubMed ID: 22233413 [TBL] [Abstract][Full Text] [Related]
8. Steatosis as a predictive factor for treatment response in patients with chronic hepatitis C. Antúnez I; Aponte N; Fernández-Carbia A; Rodríguez-Perez F; Toro DH P R Health Sci J; 2004 Jun; 23(2 Suppl):57-60. PubMed ID: 16929588 [TBL] [Abstract][Full Text] [Related]
9. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C. Zografos TA; Liaskos C; Rigopoulou EI; Togousidis E; Makaritsis K; Germenis A; Dalekos GN Am J Gastroenterol; 2008 Mar; 103(3):605-14. PubMed ID: 18190648 [TBL] [Abstract][Full Text] [Related]
10. Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C. Hézode C; Zafrani ES; Roudot-Thoraval F; Costentin C; Hessami A; Bouvier-Alias M; Medkour F; Pawlostky JM; Lotersztajn S; Mallat A Gastroenterology; 2008 Feb; 134(2):432-9. PubMed ID: 18242211 [TBL] [Abstract][Full Text] [Related]
11. Hepatitis C and steatosis. Monto A Semin Gastrointest Dis; 2002 Jan; 13(1):40-6. PubMed ID: 11944633 [TBL] [Abstract][Full Text] [Related]
13. Severity of liver disease predicts the development of glucose abnormalities in patients with chronic hepatitis B or C following achievement of sustained virological response to antiviral therapy. Chehadeh W; Al-Nakib W J Med Virol; 2009 Apr; 81(4):610-8. PubMed ID: 19235842 [TBL] [Abstract][Full Text] [Related]